This replacement post is for 10 Programmed Activities (PAs) per week to provide oncology management and treatment within the Genito-Urinary (GU) Disease Group.
The Clinical Oncologist appointed will work with the GU team to provide a comprehensive clinical service for GU patients, including patients in the outpatient, inpatient and ambulatory settings, delivering Radiotherapy and Systemic Anti‑Cancer Therapy (SACT) whilst also providing Clinical Oncology input to the GU MDT.
The GU Disease Group led by Professor Ananya Choudhury consists of 11 Clinical Oncologists. These oncologists manage all GU cancers diagnosed within the Greater Manchester and Cheshire Cancer Network, with many oncologists delivering a peripheral/Christie @ service through MDTs and clinics. Systemic therapy is delivered centrally or given to patients at peripheral or outreach clinics according to agreed protocols. Radiotherapy is delivered at The Christie or at our satellite units in Salford, Oldham and Macclesfield.
The group has an active prostate brachytherapy service, and the team has a strong commitment to research and trial activity in which the appointee would be expected to be involved in.
Systemic treatment for Germ Cell and renal is provided by the Medical Oncologist at the Christie. All Disease Group consultants work as part of a multi‑disciplinary team supporting the delivery of this work including 5 Nurse Clinicians/Advanced Clinical Practitioners (including trainee’s), 4.8 Clinical Nurse Specialists, 4 Clinical Research Fellows, 4 Specialist Trainees, 1 Pharmacist and 4.5 Research Nurses.
The appointee will serve the South Sector MDT which takes referrals from Stockport, Macclesfield and Tameside.
The urology group has an established record in radiotherapy related research with an internationally recognized programme of research. Radiotherapy‑related research is led by Professor Ananya Choudhury and the urology team have monthly multi‑disciplinary radiotherapy research meetings with regular attendance by radiographers, physicists and clinicians. There is also a monthly research seminar at which all ongoing research is presented by surgical, radiotherapy and systemic teams. Systemic and novel agent clinical trials are led by Dr A Hudson. The GU clinical oncology group has an broad clinical trial portfolio with phase I/II/III trials delivering research studies to ~150‑200 patients per year.
Role responsibilities
* Management of patients with Prostate and Bladder cancer receiving standard therapy including treatment decisions and ongoing care.
* Participating in all relevant aspects of clinical governance, including maintaining up to date protocols, guidelines and clinical audit.
* Contributing to current research projects and establish new opportunities to expand and develop research within the team.
* Revision and development of evidence‑based protocols for patients and undertaking the administrative duties associated with the care of their patients.
* Maintaining a level of continuing professional development consistent with the recommendations of the Royal College of Radiologists.
* Actively contributing to the training of junior doctors and other multi‑disciplinary team members in both in‑patient and outpatient departments.
DUTIES AND RESPONSIBILITIES
The appointee will be expected to develop a significant urology interest delivering both radiotherapy and systemic therapy. The post involves four clinics, two seeing new patients and two for complex follow up patients. At present any patients requiring intravenous systemic therapy attend the Christie site to receive this treatment.
The appointee will serve the South Sector MDT which takes referrals from Stockport, Macclesfield and Tameside. This will include attendance at the specialist Urology MDT.
The South Sector uro‑oncology MDT service is an established team comprising of clinical oncologists, urologists (performing level 2 surgery), pathologists, radiologists and clinical nurse specialists in addition to a MDT Co‑ordinator.
The Clinical Oncology Urology group provide a comprehensive range of treatment options including VMAT/IGRT radiotherapy, LDR/HDR brachytherapy, prostate SABR, oligometastatic SABR and delivery of radionucleotide therapies e.g. Ra223. The provision of chemotherapy for prostate and urothelial cancers is also delivered by the clinical oncology team with renal cancer and testicular cancer systemic therapies undertaken by the medical oncology team.
The appointee will primarily be based at The Christie with the expectation that one clinic will be held at one of our Christie @ locations and will provide input to the following areas of delivery:
* Outpatient clinics – Providing support with waiting times across Greater Manchester and Cheshire.
* Radiotherapy and SACT Services.
* Inpatient Services – primarily Wards 4, 11, 12, 14 and 15 and the Oncology Assessment Unit.
* Multi‑Disciplinary Team meetings.
* Team meetings.
* Radiotherapy Peer Review.
* Educational meetings.
* Audit.
* Urology Advanced Practitioner lead – supervisor.
* SABR development.
* Radionucleotide therapy lead.
The postholder will be expected to see approximately ~200‑300 new patients per year.
The appointee will have access to office accommodation and secretarial support.
Job Plan Timetable
* Monday
* Tuesday
* Wednesday
* Thursday
* Friday
* AM
* SPA
* (1PA)
* SACT clinic cover 1 in 2 (0.5PA)
* Admin (0.5PA)
* Penile clinic cover and MDT (1:4) (0.25 PA)
* Admin (0.75PA)
* NP clinic at SHH
* (0.5 PA)
* MDT
* (0.5PA)
* Radionucleotide clinic
* (1PA)
* PM
* SPA
* (1PA)
* Complex follow-up clinic Christie
* (1PA)
* Peer Review (0.125PA)
* SABR development
* (0.375PA)
* SPA (0.5)
* NP clinic at SHH (1PA)
* RT Planning / SABR
* (1PA)
On call Commitments
This role does require participation in the on‑call rota. The on‑call rota involves a commitment to a full week (1: 20 rotation). The on‑call consultant provides input to the acute admissions unit at the weekend.
This advert closes on Wednesday 14 Jan 2026
#J-18808-Ljbffr